Skip To Main Content
Chi-Ying F on Muck Rack

Chi-Ying F

As seen in: Biomed Central (BMC), Journal of Biomedical Science
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chi-Ying

Contact Chi-Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions - Cancer Cell International

|
By Peter Mu-Hsin, Chi-Ying F, Zhongxiao Branch, Minh Tran-Binh
| Biomed Central (BMC)
The DepMap portal (https://depmap.org/portal/) [24] serves as a comprehensive repository for multiomics databases since it incorporates datasets from the Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) and Cancer Cell Line Encyclopedia (CCLE) databases. The PRISM database contains drug sensitivity screening data for 4,686 compounds found in 750 cells.
Open in Who Shared Issue with article?

Engineered extracellular vesicles carrying let-7a-5p for alleviating inflammation in acute lung injury - Journal of Biomedical Science

|
By Ly James, Chi-Ying F, Chang Gung College, Bionet Therapeutics
| Journal of Biomedical Science Verified
Bionet Therapeutics, Taiwan, kindly provided WJ-MSCs for EV production and all subsequent in vitro and in vivo experiments. Cell analysis through flow cytometry was conducted to confirm the presence of specific markers (for MSCs: CD105+, CD44+, CD29+, CD90+, CD73+, CD13+, CD45−, CD14−, CD34−, CD31−, CD19−, and HLA-DR−) before their use.
Open in Who Shared Issue with article?

Repurposing thioridazine for inducing immunogenic cell death in colorectal cancer via eIF2α/ATF4/CHOP and secretory autophagy pathways

|
By Chi-Ying F
| paperity.org
Cell Communication and Signaling, Jul 2023 Colorectal cancer (CRC) is a highly prevalent cancer type with limited targeted therapies available and 5-year survival rate, particularly for late-stage patients. There have been numerous attempts to repurpose drugs to tackle this problem. It has been reported that autophagy inducers could augment the effect of certain chemotherapeutic agents by enhancing immunogenic cell death (ICD).
Open in Who Shared Issue with article?
See all 4 articles